Full Press Release Details
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN:US74154B2034)
PRIMA NAMES NEW CHIEF FINANCIAL OFFICER AND NEW COMPANY SECRETARY IN MANAGEMENT
BioMed Ltd (ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034) ( Prima, the Company ) announced today the following changes in senior management.
Marc Voigt, the Company s current Chief Business Officer, will assume the Chief Financial Officer role effective November 16, 2012. With immediate effect, Deanne Miller, LLB, has been appointed
General Counsel and co-Company Secretary with Ian Bangs, Prima s current CFO and Company Secretary. Ms Miller will take over as the sole Company Secretary effective November 16, 2012.
The reorganisation is intended to support the Company s development, especially as the US and European operations take on
increasing importance, and to reduce the Company s administrative costs. Matthew Lehman, Prima s Chief Executive Officer, explained We are very excited about our development program for CVac and look forward to capitalising on our strengths in the field of personalised bio-therapeutics. To support our
strategy, we need to maximise funds available for our research and development. It makes good sense to bring our legal expertise in-house and to streamline some of our administrative and finance functions to outside of Australia. I am confident that
the addition of Ms Miller to the team and Mr Voigt s appointment to CFO will benefit the Company substantially.
November 16, Mr. Bangs will assist with a transition period through December 31, 2012. We are very appreciative of Ian s service to Prima, said Matthew Lehman, Ian was the Company s first full-time and
in-house CFO. He has significantly contributed to Prima s corporate development and played a crucial role in the previous capital raising and leading the preparations for our NASDAQ listing. We thank him for his contribution and wish him all
the very best for the future.
Deanne Miller, LLB, earned her LLB (Hons) and BCom (finance and accounting double major) from the
University of Sydney. She brings strong experience in corporate law, tax, and regulatory compliance, having held various positions of increasing responsibility at organisations such as KPMG, Westfield Group, Australian Securities and Investments
Commission (ASIC), Macquarie Group, and Westpac Group.
Ms Miller will be based in Sydney. Mr Voigt is based in Berlin, Germany.
Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is
dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Prima s lead product is CVac , an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.
Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284
For further information please contact:
Australia Investor/Media:
Mr. James Moses, Mandate Corporate
+61 (0) 420 991 574; james@mandatecorporate.com.au
Ms. Kathy Galante, Burns McClellan Inc.
+1 (212) 213-0006; kgalante@burnsmc.com
Europe Investor/Media:
M hlhaus, edicto GmbH
+49 (0) 69 905505-52; amuehlhaus@edicto.de
Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284